Clinical Trials
6 trialsNCT06522737 2026-04-06
TERZO
SecuraBio
Phase 3 Recruiting
NCT04083495 2025-09-22
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT01716806 2024-06-11
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Seagen Inc.
Phase 2 Completed
NCT02168140 2024-02-13
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Wake Forest University Health Sciences
Phase 1 Completed
NCT01644253 2021-05-20
Phase 1b Safety and Efficacy Study of TRU-016
Aptevo Therapeutics
Phase 1 Terminated
NCT01110135 2017-05-24
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma
University of Washington
Phase 2 Completed